医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Laboratories announces the launch of Melphalan Hydrochloride for Injection in the U.S. Market

2017年12月26日 PM06:37
このエントリーをはてなブックマークに追加


 

HYDERABAD, India & PRINCETON, N.J.

Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of Alkeran® (melphalan hydrochloride) for Injection in the United States market approved by the U.S. Food and Drug Administration (USFDA).

The Alkeran® brand and generic had U.S. sales of approximately $107 million MAT for the most recent twelve months ending in October 2017 according to IMS Health*.

Dr. Reddy’s Melphalan Hydrochloride for Injection is available in a carton containing one single-dose clear glass vial of freeze-dried melphalan hydrochloride equivalent to 50 mg melphalan and one 10 mL clear glass vial of sterile diluent.

 

WARNING

Melphalan hydrochloride for injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing intravenous (IV) to oral melphalan have shown more myelosuppression with the IV formulation. Hypersensitivity reactions, including anaphylaxis, have occurred in approximately 2% of patients who received the IV formulation. Melphalan is leukemogenic in humans. Melphalan produces chromosomal aberrations in vitro and in vivo and, therefore, should be considered potentially mutagenic in humans.

Please see http://www.drreddys.com/pi/melalphalan.pdf for Full Prescribing Information including Boxed Warning.

Alkeran® is a registered trademark of Apotex, Inc.

*IMS National Sales Perspective: Retail and Non-Retail MAT October 2017
DY-1217-189

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171226005110/en/

CONTACT

Dr. Reddy’s Laboratories Ltd
INVESTOR RELATIONS
SAUNAK SAVLA
(Ph:
+91-40-49002135)
saunaks@drreddys.com
or
MEDIA
RELATIONS
CALVIN PRINTER
(Ph: +91-40- 49002121)
calvinprinter@drreddys.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightreeがアテナヘルスと電子的患者紹介システムのインテグレーションを発表
  • PHCホールディングス株式会社: NPO法人 日本医療ネットワーク協会と、医療データ連携の実証実験に関する業務委託契約を締結
  • Dr. Reddy’s Laboratories defends its right to launch Buprenorphine and Naloxone Sublingual Film in the U.S. Market
  • Dr. Reddy’s Laboratories Limited announces filing of Annual Report on Form 20-F
  • Dr. Reddy’s Laboratories Announces USFDA Final Approval and Launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market